Compugen Establishes Small-Molecule, Drug Discovery Subsidiary

Tel Aviv, Israel-based Compugen last week announced Keddem Bioscience Limited, a small-molecule drug discovery company that formerly was the company’s chemistry division. The subsidiary’s offices and labs are located in Ashkelon, Israel.

The company said that its Keddem subsidiary would approach drug discovery by proposing the creation of a comprehensive, yet relatively small set of screening molecules (less than 100,000), and a suite of algorithms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.